NEXT Financial Group Inc Buys 856 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

NEXT Financial Group Inc increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 127.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,526 shares of the medical research company’s stock after purchasing an additional 856 shares during the period. NEXT Financial Group Inc’s holdings in Thermo Fisher Scientific were worth $448,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Truvestments Capital LLC bought a new position in Thermo Fisher Scientific in the first quarter valued at approximately $29,000. CX Institutional bought a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at $36,000. Somerset Trust Co increased its stake in shares of Thermo Fisher Scientific by 162.7% in the 1st quarter. Somerset Trust Co now owns 197 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 122 shares during the last quarter. Farmers & Merchants Trust Co of Chambersburg PA increased its stake in shares of Thermo Fisher Scientific by 168.0% in the 1st quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 201 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 126 shares during the last quarter. Finally, Cullen Frost Bankers Inc. bought a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at $64,000. 87.97% of the stock is currently owned by hedge funds and other institutional investors.

TMO traded down $2.99 during trading on Friday, reaching $274.82. 2,096,269 shares of the company’s stock were exchanged, compared to its average volume of 1,315,506. The company has a quick ratio of 1.07, a current ratio of 1.49 and a debt-to-equity ratio of 0.58. Thermo Fisher Scientific Inc. has a one year low of $208.34 and a one year high of $305.45. The stock has a market capitalization of $111.07 billion, a PE ratio of 23.69, a PEG ratio of 1.82 and a beta of 1.11. The stock has a fifty day moving average price of $291.36.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $3.04 earnings per share for the quarter, topping the consensus estimate of $3.01 by $0.03. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.11%. The company had revenue of $6.32 billion for the quarter, compared to analysts’ expectations of $6.31 billion. During the same quarter in the previous year, the firm posted $2.75 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 3.9% on a year-over-year basis. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 12.23 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Tuesday, September 17th will be given a $0.19 dividend. The ex-dividend date is Monday, September 16th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.83%.

In related news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $284.83, for a total value of $14,241,500.00. Following the sale, the chief executive officer now directly owns 342,193 shares in the company, valued at $97,466,832.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Stephen Williamson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $268.29, for a total value of $670,725.00. Following the completion of the sale, the chief financial officer now owns 40,029 shares in the company, valued at $10,739,380.41. The disclosure for this sale can be found here. Insiders sold a total of 52,775 shares of company stock worth $14,986,676 in the last quarter. Corporate insiders own 0.45% of the company’s stock.

A number of research analysts have issued reports on the company. Barclays set a $330.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Monday, July 15th. Bank of America reaffirmed a “buy” rating and set a $300.00 price target (up from $285.00) on shares of Thermo Fisher Scientific in a report on Tuesday, April 16th. Wolfe Research began coverage on shares of Thermo Fisher Scientific in a report on Thursday, May 30th. They set an “outperform” rating on the stock. UBS Group boosted their target price on shares of Thermo Fisher Scientific from $305.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, May 23rd. Finally, Credit Suisse Group reaffirmed a “buy” rating and set a $310.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Thermo Fisher Scientific presently has a consensus rating of “Buy” and a consensus target price of $303.17.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Article: Institutional Investors

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.